- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06178432
Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)
A Single-arm, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Efficacy of CRG003 Injection in the Treatment of Late Onset Pompe Disease
This is a single-center, single-arm, open-label, single-dose treatment clinical study to evaluate the safety, tolerability and efficacy of CRG003 injection in participants with late onset Pompe disease (LOPD), with a long-term follow-up period of 5 years.
CRG003 (BBM-G102) injection is an adeno-associated virus (AAV) gene therapy product for treating Pompe disease to stably express active GAA enzyme in the liver on a long-term basis after the injection.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Wenhua Zhu, MD,PhD
- Phone Number: 8160 +8621-52889999
- Email: zhuwenhua@huashan.org.cn
Study Locations
-
-
-
Shanghai, China
- Huashan Hospital of Fudan University
-
Contact:
- Wenhua Zhu, MD,PhD
- Phone Number: 8160 +8621-52889999
- Email: zhuwenhua@huashan.org.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants voluntarily sign informed consent form;
- Clinically diagnosed with LOPD;
- Males or females aged ≥ 18 years;
- Undergone enzyme replacement treatment (ERT) with recombinant human acid alpha-glucosidase (rhGAA) previously, and has been discontinued for at least four weeks before screening;
- Acceptable Pulmonary test results;
- A 6MWT ≥ 100 meters, and ambulation for 40 meters without stopping and without an assistive device;
- Acceptable laboratory values;
- Acceptable GAA anti-drug antibody titer;
- Acceptable capsid antibody titers;
- Use of reliable contraception methods during the study;
- Participants with good compliance.
Exclusion Criteria:
- Severe cardiomyopathy was defined as left ventricular ejection fraction (LVEF) < 45% or New York Heart Association (NYHA) functional class 3 or above;
- Require invasive mechanical ventilation, or rely on noninvasive ventilation during the day;
- Intolerance to ERT, prior experience of serious infusion-associated reactions (IARs), prior experience of serious allergic reactions or investigator-assessed intolerance to ERT;
- Have received any systemic immunosuppressants (except inhalation or topical use) other than glucocorticoids or investigator-recommended immunosuppressants 30 days prior to screening, and known intolerance to immunosuppressants such as glucocorticoids;
- Positive for hepatitis B surface antigen (HBsAg) or hepatitis B virus DNA (HBV-DNA), positive for hepatitis C virus RNA (HCV-RNA). Participants with a history of hepatitis B or C can be regarded as negative if both two samples collected at an interval of at least three months are tested negative for the above parameters; positive for human immunodeficiency virus (HIV) or positive serologic test for syphilis;
- Currently on antiviral therapy for hepatitis B or C;
- Have clinical organic diseases (except symptoms or diseases associated with Pompe disease), including active tuberculosis, cardiovascular and cerebrovascular diseases, hepatobiliary system, respiratory system, nervous system, urinary system, or endocrine system disorders (such as diabetes, etc.), or other serious complications, or other conditions that make the patients not eligible for the study according to the investigator;
- Have underlying liver diseases, e.g., prior diagnosis of portal hypertension, splenomegaly, hepatic encephalopathy, severe fatty liver, cirrhosis or liver fibrosis ≥stage 3; or ultrasound-identified liver neoplasms or laboratory tests suggesting elevated alpha-fetoprotein, etc., which are considered by the investigator as clinically significant;
- Have received gene therapy prior to screening or used other investigational drugs or drugs that affect this study as evaluated by the investigator within four weeks prior to screening or within 5 half lives of the investigational drug (whichever is longer);
- Have received or will receive any herbal preparations (herbal supplements or traditional Chinese medicines derived from plants, minerals, or animals, other than topical medications) that may affect liver function or Chinese herbal medicines that may affect the study as judged by the investigator four weeks prior to study medication or during the study follow-up period;
- Alcohol dependence or drug addiction, and inability to stop alcohol intake as ordered by the doctor during the study;
- Have received any live vaccine two months predose or history of vaccination within 30 days prior to screening or planning to receive vaccination during the screening and the main study period;
- Pregnant or lactating female participants;
- Other conditions that make the participants not eligible for the study according to the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm of CRG003 injection
The dose of CRG003 injection will be calculated according to the participant's weight with single intravenous infusion.
|
The dose of CRG003 will be calculated according to the participant's weight with single intravenous infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of dose limited toxicities
Time Frame: 12 weeks
|
Incidence of dose limited toxicities (DLTs) as determined by the safety review committee (SRC) within 12 weeks following CRG003 infusion;
|
12 weeks
|
Incidence of adverse events and serious adverse events
Time Frame: 26 weeks and 52 weeks
|
Incidence of adverse events (AEs) and serious adverse events (SAEs) within 26 weeks and 52 weeks following CRG003 infusion
|
26 weeks and 52 weeks
|
The change of hepatic enzyme concentration
Time Frame: 26 weeks and 52 weeks
|
Alkaline phosphatase (ALP)
|
26 weeks and 52 weeks
|
Changes from baseline in liver function
Time Frame: 26 weeks and 52 weeks
|
Changes from baseline in liver function [Alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT) and total bilirubin (TBIL)] within 26 weeks and 52 weeks following CRG003 infusion
|
26 weeks and 52 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chongbo Zhao, MD,PhD, Huashan Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Lysosomal Storage Diseases, Nervous System
- Glycogen Storage Disease
- Glycogen Storage Disease Type II
Other Study ID Numbers
- KY2023-783
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pompe Disease (Late-onset)
-
University of Erlangen-Nürnberg Medical SchoolRecruitingPompe Disease (Late-onset) | Pompe Disease | Pompe's Disease Juvenile Onset | Pompe Disease Infantile-OnsetGermany
-
Indiana UniversityNational Institute on Aging (NIA)RecruitingDementia | Alzheimer Disease, Late OnsetUnited States
-
Ohio State UniversityCompletedAlzheimer Disease, Late OnsetUnited States
-
NeuroEM Therapeutics, Inc.University of South Florida Health / Byrd Alzheimer's InstituteUnknownAlzheimer Disease | Alzheimer Disease, Late OnsetUnited States
-
Universitaire Ziekenhuizen KU LeuvenUnknownAlzheimer Disease, Late OnsetBelgium
-
University of MinnesotaMayo Clinic; National Institute on Aging (NIA); University of St ThomasCompletedAlzheimer's Disease, Late OnsetUnited States
-
NeuroEM Therapeutics, Inc.Invicro, Boston; Byrd Alzheimer's Institute, University of South Florida; University... and other collaboratorsCompletedAlzheimer Disease | Alzheimer Disease, Late OnsetUnited States
-
Federal University of Minas GeraisCompletedAlzheimer Disease, Late Onset
-
IRCCS Centro San Giovanni di Dio FatebenefratelliI.R.C.C.S. Fondazione Santa Lucia; Ministero della Salute, ItalyRecruitingAlzheimer Disease | Alzheimer Disease, Late Onset | Cognitive DeteriorationItaly
-
Tamir Ben-HurHebrew University of JerusalemEnrolling by invitationAlzheimer Disease, Late OnsetIsrael
Clinical Trials on CRG003 injection
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
United States Naval Medical Center, San DiegoCEL-SCI CorporationTerminated
-
National Taiwan University HospitalCompleted
-
Royan InstituteCompletedMyocardial InfarctionIran, Islamic Republic of